BARTHELEMY NICOLAS
BARTHELEMY NICOLAS's purchase track record
BARTHELEMY NICOLAS has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/14/2024 | RGEN | $151K | +11.4% | +24.5% | +11.4% |
| 5/11/2022 | TWST | $250K | +97.8% | +6.8% | -4.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Twist Bioscience highlighted in AI biofoundry and analyst upgrades. Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.
Transaction History
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| RGEN | ▲ Buy | Open Market | 1,200 | $151K | 6/14/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 701 | $0 | 5/16/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 686 | $0 | 5/18/2023 | View on chart |
| TWST | ▲ Buy | Option Exercise | 9,082 | $212K | 11/21/2022 | View on chart |
| MASS | ▲ Buy | Option Exercise | 1,379 | — | 6/15/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 534 | $0 | 5/26/2022 | View on chart |
| TWST | ▲ Buy | Open Market | 8,550 | $250K | 5/11/2022 | View on chart |
| LAB | ▲ Buy | Option Exercise | 20,993 | $79K | 4/1/2022 | View on chart |
| LAB | ▲ Buy | Option Exercise | 5,000 | $17K | 3/31/2022 | View on chart |
| TWST | ▲ Buy | Grant | 3,491 | $0 | 2/8/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 1,285 | $165K | 10/29/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,285 | $370K | 10/29/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 360 | $104K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.